Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2011; 32(04): 238-241
DOI: 10.4103/0971-5851.95150
CASE REPORT

Neonatal Kasabach-Merritt phenomenon

Dinesh Yadav
Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children′s Hospital, New Delhi, India
,
Anu Maheshwari
Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children′s Hospital, New Delhi, India
,
Satinder Aneja
Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children′s Hospital, New Delhi, India
,
Anju Seth
Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children′s Hospital, New Delhi, India
,
Jagdish Chandra
Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children′s Hospital, New Delhi, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Kasabach-Merritt phenomenon (KMP) is a life-threatening consumptive coagulopathy in the presence of a rapidly enlarging vascular tumor. It usually presents in early infancy, but onset in early neonatal period, facial hemangioma, and vincristine use in neonates has rarely been reported. We, hereby, present a 6-day-old male child presenting with facial hemangioma and intracranial hemorrhage, and KMP responding well to steroids and vincristine. Pathophysiology of disease and various treatment options have been discussed.

Keywords

Kasabach-Merritt phenomenon - neonate - vincristine


Publication History

Article published online:
06 August 2021

© 2011. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kelly M. Kasabach-Merritt Phenomenon. Pediatr Clin North Am 2010;57:1085-9.
  • 2 Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: Report of a case. Am J Dis Child 1940;59:1063-70.
  • 3 Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, et al. Kasabach-Merritt phenomenon: A retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002;24:459-62.
  • 4 Shin HY, Ryu KH, Ahn HS. Stepwise multimodal approach in the treatment of Kasabach-Merritt syndrome. Pediatr Int 2000;42:620-4.
  • 5 Wananukul S, Nuchprayoon I, Seksarn P. Treatment of Kasabach-Merritt syndrome: A stepwise regimen of prednisolone, dipyridamole, and interferon. Int J Dermatol 2003;42:741-8.
  • 6 Hesselmann S, Micke O, Marquardt T, Baas S, Bramswig JH, Harms E, et al. Kasabach-Merritt syndrome: A review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha. Br J Radiol 2002;75:180-4.
  • 7 Abass K, Saad H, Kherala M, Elsayed AA. Successful treatment of Kasabach-Merritt syndrome with vincristine and surgery: A case report and review of literature. Cases J 2008;1:1.
  • 8 Blei F, Karp N, Rofsky N, Rosen R, Greco MA. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: Case report and review of literature. Pediatr Hematol Oncol 1998;15:295-305.
  • 9 Dresse MF, David M, Hume H, Blanchard H, Russo P, Van Doesberg N, et al. Successful treatment of Kasabach Merritt syndrome with Prednisolone and epsilon aminocaproic acid. Pediatr Hematol Oncol 1991;8:329-34.
  • 10 Hall DG. Kasabach-Merritt syndrome: Pathogenesis and management. Br J Hematol 2001;112:851-62.
  • 11 Enjolras O, Mulliken JB, Wassef M, Frieden IJ, Rieu PN, Burrows PE, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 2000;42:225-35.